Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Diabetologie
Erschienen in: Die Diabetologie 5/2022

13.06.2022 | Typ-2-Diabetes | DDG Praxisempfehlungen

Therapie des Typ-2-Diabetes

verfasst von: Prof. Dr. med. Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel

Erschienen in: Die Diabetologie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​deutsche-diabetes-gesellschaft.​de/​behandlung/​leitlinien) befinden sich alle PDF zum kostenlosen Download. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Nationale VersorgungsLeitlinien NVL-2-Diabetes – Teilpublikation, 2. Aufl.
2.
Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657PubMedCrossRef
3.
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(04):347–357PubMedCrossRef
4.
Furtado RHM, Bonaca MP, Raz I (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139(22):2516–2527PubMedCrossRef
5.
Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139(22):2528–2536PubMedCrossRef
6.
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128PubMedCrossRef
7.
Cannon CP, McGuire DK, Pratley R, VERTIS-CV Investigators et al (2018) Design and baseline characteristics of the evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV). Am Heart J 206:11–23PubMedCrossRef
8.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130PubMedCrossRef
9.
Pasternak B, Wintzell V, Eliasson B et al (2020) Use of glucagon like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43:1326–1335PubMedCrossRef
10.
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844PubMedCrossRef
11.
12.
Hernandez AF, Green JB, Janmohamed S et al (2018) Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet 392:1519–1529PubMedCrossRef
13.
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239PubMedCrossRef
14.
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257PubMedCrossRef
15.
Preshaw PM, Alba AL, Herrera D et al (2012) Periodontitis and diabetes: a two-way relationship. Diabetologia 55:21–31PubMedCrossRef
16.
17.
Wang R, Song Y, Yan Y et al (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis 254:193–199PubMedCrossRef
18.
Parhofer KG, Birkenfeld AL, Krone W et al (2020) Lipidtherapie bei Patienten mit Diabetes mellitus. Diabetologie 15(1):S160–S165
19.
Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188PubMedCrossRef
20.
The Task Force for the management of arterial hypertension of the European Society of cardiology (ESC), European Society of Hypertension (ESH) (2018) 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104CrossRef
21.
Heinemann L, Kaiser P, Freckmann G et al (2018) HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose? Diabetologie 13:46–53CrossRef
22.
Landgraf R, Nauck M, Freckmann G et al (2018) Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen? Dtsch Med Wochenschr 143:1549–1555PubMedCrossRef
23.
Nauck M, Gerdes C, Petersmann A et al (2020) Definition, Klassifikation und Diagnostik des Diabetes mellitus. Update 2020. Diabetologie 15(1):S9–S17
24.
Landgraf R (2021) HbA1c in der Diabetesdiagnostik. Der Goldstandard? Diabetes Aktuell 19:22–29CrossRef
25.
Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369PubMedCrossRef
26.
Zaharia OP, Strassburger K, Strom A, German Diabetes Study Group et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5‑year follow-up study. Lancet Diabetes Endocrinol 7(9):684–694PubMedCrossRef
27.
Dennis JM, Shields BM, Henley WE et al (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7(6):442–451PubMedPubMedCentralCrossRef
28.
Zhang Y, Pan XF, Chen J et al (2020) Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 63:21–3316PubMedCrossRef
29.
30.
Forouhi NG, Misra A, Mohan V et al (2018) Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 361:k2234PubMedPubMedCentralCrossRef
31.
Serra-Majem L, Román-Viñas B, Sanchez-Villegas A et al (2019) Benefits of the Mediterranean diet: epidemiological and molecular aspects. Mol Aspects Med 67:1–55PubMedCrossRef
32.
Taylor R, Al-Mrabeh A, Sattar N (2019) Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 7(9):726–736PubMedCrossRef
33.
Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 42(5):731–754PubMedPubMedCentralCrossRef
34.
Hauner H (2021) Evidenz in der Ernährungstherapie des Diabetes mellitus. Diabetologe (published online 29.06.2021)
35.
Chester B, Babu JR, Greene MW et al (2019) The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 35:e3188PubMedCrossRef
36.
Kempf K, Altpeter B, Berger J et al (2017) Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: a randomized controlled trial. Diabetes Care 40(7):863–871PubMedCrossRef
37.
Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2‑year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol 7:344–355PubMedCrossRef
38.
Adipositas – Prävention und Therapie (AWMF-Register Nr. 050-001)
39.
Aberle J, Lautenbach A, Meyhöfer S et al (2021) Adipositas und Diabetes. Diabetologe 16(2):S290–S298
40.
Yang D, Yang Y, Li Y et al (2019) Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 74(4):313–321PubMedCrossRef
41.
Tarp J, Støle AP, Blond K et al (2019) Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 62:1129–1142PubMedPubMedCentralCrossRef
42.
43.
Esefeld K, Kress S, Behrens M et al (2021) Diabetes, Sport und Bewegung. Diabetologe 16(2):S299–S307
44.
Piercy KL, Richard P, Troiano RP et al (2018) The physical activity guidelines for Americans. JAMA 320(19):2020–2028PubMedCrossRef
45.
46.
Pan A, Wang Y, Talaei M et al (2015) Relation of active, passive, and quitting smoking with incident diabetes: a meta-analysis and systematic review. Lancet Diabetes Endocrinol 3(12):958–996PubMedPubMedCentralCrossRef
47.
Kar D, Gillies C, Nath M et al (2019) Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 56:839–850PubMedPubMedCentralCrossRef
48.
S3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung (Langversion AWMF-Register Nr. 076-006)
49.
50.
Nationale VersorgungsLeitlinien NVL-2-Diabetes – Teilpublikation, 2. Aufl.
51.
Ärztliches Zentrum für Qualität in der Medizin, Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften et al (2020) Nationale VersorgungsLeitlinie Typ-2-Diabetes, 2. Aufl. (Konsultationsfassung. AWMF-Register-Nr.: nvl-001)
52.
Fleming GA, Petrie JR, Bergenstal RM et al (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European association for the study of diabetes (EASD) and the American diabetes association (ADA) diabetes technology working group. Diabetes Care 43(01):250–260. https://​doi.​org/​10.​2337/​dci19-0062CrossRefPubMed
53.
Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20:427–437PubMedCrossRef
54.
Matthews DR, Paldánius PM, Proot P, VERIFY study group et al (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5‑year, multicentre, randomised, double-blind trial. Lancet 394:1519–1529. https://​doi.​org/​10.​1016/​S0140-6736(19)32131-2CrossRefPubMed
55.
Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2(11):885–893PubMedCrossRef
56.
Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37(10):2763–2773PubMedCrossRef
57.
Ahmann A, Rodbard HW, Rosenstock J et al (2015) Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo controlled trial. Diabetes Obes Metab 17:1056–1064PubMedPubMedCentralCrossRef
58.
Montvida O, Klein K, Kumar S et al (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide‑1 receptor agonists: a real-world study in 66 583 patients. Diabetes Obes Metab 19(01):108–117PubMedCrossRef
59.
Billings LK, Doshi A, Gouet D et al (2018) Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care 41(05):1009–1016PubMedCrossRef
60.
Parhofer KG (2021) Lipidtherapie. Diabetologe 16(02):S312–S317
61.
Mengden T, Weisser B (2021) Therapieüberwachung bei arterieller Hypertonie. Dtsch Arztebl 118(27):473–478
62.
63.
64.
American Diabetes Association (2021) Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care 44(1):S125–S150CrossRef
65.
The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCentralCrossRef
66.
Banegas JR, Ruilope LM, de la Sierra A et al (2018) Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 378:1509–1520PubMedCrossRef
67.
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645PubMedCrossRef
68.
The Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154PubMedCentralCrossRef
69.
Unick JL, Gaussoin SA, Hill JO et al (2017) Objectively assessed physical activity and weight loss maintenance among individuals enrolled in a lifestyle intervention. Obesity (Silver Spring) 25(11):1903–1909CrossRef
70.
The Look AHEAD Research Group (2016) Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol 4:913–921CrossRef
71.
Gregg EW, Lin J, Bardenheier B et al (2018) Impact of intensive lifestyle intervention on disability-free life expectancy: the look AHEAD study. Diabetes Care 41:1040–1048PubMedPubMedCentralCrossRef
72.
Chao AM, Wadden TA, Berkowitz RI, Look AHEAD Research Group et al (2020) Weight change 2 years after termination of the intensive lifestyle intervention in the look AHEAD study. Obesity 28:893–890PubMedCrossRef
73.
Yang D, Yang Y, Li Y et al (2019) Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 74(04):313–321PubMedCrossRef
74.
Tarp J, Støle AP, Blond K et al (2019) Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 62:1129–1142PubMedPubMedCentralCrossRef
75.
Liu Y, Ye W, Chen Q et al (2019) Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 16(01):E140PubMedCrossRef
76.
77.
Lazarus B, Wu A, Shin JI et al (2018) Association of metformin use with risk of lactic acidosis across the range of kidney function. A community-based cohort study. JAMA Intern Med 178(07):903–910PubMedPubMedCentralCrossRef
78.
Griffin SJ, Leaver JK, Irving GJ et al (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomized trails among people with type 2 diabetes. Diabetologia 60:1620–1629PubMedPubMedCentralCrossRef
79.
Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 316(03):313–324PubMedCrossRef
80.
Madsen KS, Kähler P, Kähler LKA et al (2019) Metformin and second- or third generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD12368PubMed
81.
Sattar N, McGuire DK (2021) Prevention of CV outcomes in antihyperglycemic drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J 42:2574–2576PubMedCrossRef
82.
Rena G, Mordi IR, Lang CC (2020) Metformin: still the sweet spot for CV protection in diabetes? Curr Opin Pharmacol 54:202–208PubMedCrossRef
83.
Mallik R, Chowdhury TA (2018) Metformin in cancer. Diabetes Res Clin Pract 143:409–419PubMedCrossRef
84.
Thakur S, Daley B, Klubo-Gwiezdzinska J (2019) The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol. DOI: JME-19–0083.R1
85.
86.
87.
88.
89.
90.
Park YMM, Bookwalter DB, O’Brien KM et al (2021) A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. Ann Oncol 32:351–359PubMedCrossRef
91.
Lv Z, Guo Y (2020) Metformin and its benefits for various diseases. Front Endocrinol 11:191CrossRef
92.
Khunti K, Knighton P, Zaccardi F et al (2021) Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 9:293–303PubMedPubMedCentralCrossRef
93.
Wargny M, Potier L, Gourdy P et al (2021) Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia 64:778–794PubMedPubMedCentralCrossRef
94.
Kow CS, Hasan SS (2021) Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. J Med Virol 93:695–697PubMedCrossRef
95.
Lim S, Bae JH, Kwon H‑S, Nauck MA (2021) COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 17:11–13PubMedCrossRef
96.
Bornstein SR, Rubino F, Khunti K et al (2020) Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 8:546–550PubMedPubMedCentralCrossRef
97.
Oshima M, Jun M, Ohkuma T et al (2019) The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 62:1988–1997PubMedPubMedCentralCrossRef
98.
The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
99.
Rosenstock J, Kahn SE, Johansen OE, CAROLINA Investigators et al (2019) Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322(12):1155–1166PubMedPubMedCentralCrossRef
100.
101.
Azoulay L, Suissa S (2017) Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40:706–714PubMedCrossRef
102.
Bain S, Druyts E, Balijepalli C et al (2017) Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab 19(03):329–335PubMedCrossRef
103.
Zhuang XD, He X, Yang DY et al (2018) Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166 371 participants from170 randomized controlled trials. Cardiovasc Diabetol 17(01):79PubMedPubMedCentralCrossRef
104.
Powell WR, Christiansen CL, Miller DR (2018) Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments. Diabetes Ther 9(04):1431–1440PubMedPubMedCentralCrossRef
105.
Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3(01):43–51PubMedCrossRef
106.
Hemmingsen B, Schroll JB, Lund SS et al (2013) Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD9008
107.
Hemmingsen B, Schroll JB, Wetterslev J et al (2014) Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2(03):E162–E175PubMedPubMedCentralCrossRef
108.
Vaccaro O, Masulli M, Nicolucci M et al (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomized, multicenter trial. Lancet Diabetes Endocrinol 5:887–897PubMedCrossRef
109.
Ogundipe O, Mazidi M, Chin KL et al (2021) Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase‑4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetol 58:39–46PubMedCrossRef
110.
Chen K, Kang D, Yu M et al (2018) Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase‑4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab 20:1029–1033PubMedCrossRef
111.
Patorno E, Schneeweiss S, Gopalakrishnan C et al (2019) Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride. Diabetes Care 42:2204–2210PubMedPubMedCentralCrossRef
112.
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326PubMedCrossRef
113.
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335PubMedCrossRef
114.
Green JB, Bethel MA, Armstrong PW, TECOS Study Group et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(03):232–242PubMedCrossRef
115.
Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321(01):69–79PubMedCrossRef
116.
117.
Monami M, Ahrén B, Dicembrini I et al (2013) Dipeptidyl peptidase‑4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112–120PubMedCrossRef
118.
Xu S, Zhang X, Tang L et al (2017) Cardiovascular effects of dipeptidylpeptidase‑4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgrad Med 129:205–215PubMedCrossRef
119.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319(15):1580–1591PubMedPubMedCentralCrossRef
120.
Ling J, Cheng P, Ge L et al (2019) The efficacy and safety of dipeptidyl peptidase‑4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol 56:249–272PubMedCrossRef
121.
Li L, Li S, Deng K et al (2016) Dipeptidyl peptidase‑4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 352:i610PubMedPubMedCentralCrossRef
122.
Guo WQ, Li L, Su Q et al (2017) Effect of dipeptidylpeptidase‑4 inhibitors on heart failure: a network meta-analysis. Value Health 20:1427–1430PubMedCrossRef
123.
Nauck MA, Meier JJ, Cavender MA et al (2017) Cardiovascular actions and clinical outcomes with glucagon-like peptide‑1 receptor agonists and dipeptidyl peptidase‑4 inhibitors. Circulation 136(09):849–870PubMedCrossRef
124.
Xie YY, Bowe B, Gibson AK et al (2020) Comparative effectiveness of SGLT2 inhibitors, GLP‑1 receptor agonists, DPP‑4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43:2859–2869. https://​doi.​org/​10.​2337/​dc20-1890CrossRefPubMed
125.
Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP‑4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8–16PubMedCrossRef
126.
Dougherty J, Guirguis E, Thornby KA et al (2021) A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother 55(1):65–79PubMedCrossRef
127.
Koufakis T, Mustafa OG, Zebekakis P, Kotsa K (2020) Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close T. Diabet Med 37:1418–1426PubMedCrossRef
128.
Du H, Wang DW, Chen C (2020) The potential effects of DPP‑4 inhibitors on cardiovascular system in COVID-19 patients. J Cell Mol Med 24:10274–10278PubMedPubMedCentralCrossRef
129.
130.
Tkáč I, Raz I (2017) Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 40:284–286PubMedCrossRef
131.
Pinto LC, Rados DV, Barkann SS et al (2018) Dipeptidyl peptidase‑4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 8(01):782PubMedPubMedCentralCrossRef
132.
133.
Overbeek JA, Bakker M, van der Heijden AAWA et al (2018) Risk of dipeptidyl peptidase‑4 (DPP-4) inhibitors on site specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev 34:e3004PubMedCrossRef
134.
Abrahami D, Douros A, Yin H et al (2018) Dipeptidyl peptidase‑4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 360:k872PubMedPubMedCentralCrossRef
135.
Li G, Crowley MJ, Tang H et al (2019) Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 42(07):e119–e121PubMedPubMedCentralCrossRef
136.
Storgaard H, Gluud LL, Bennett C et al (2016) Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 11(11):e166125PubMedPubMedCentralCrossRef
137.
Monami M, Liistro F, Scatena A et al (2018) Short and medium-term efficacy of sodium glucose co-transporter‑2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 20(05):1213–1222PubMedCrossRef
138.
Usman MS, Siddiqi TJ, Memon MM et al (2018) Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 25(05):495–502PubMedCrossRef
139.
Mishriky BM, Tanenberg RJ, Sewell KA et al (2018) Comparing SGLT‑2 inhibitors to DPP‑4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 44(02):112–120PubMedCrossRef
140.
Seidu S, Kunutsor SK, Cos X et al (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes 12(03):265–283PubMedCrossRef
141.
Rådholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter‑2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes—a systematic review. Diabetes Res Clin Pract 140:118–128PubMedCrossRef
142.
Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP‑4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8–16PubMedCrossRef
143.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319(15):1580–1591PubMedPubMedCentralCrossRef
144.
Aronson R, Frias J, Goldman A et al (2018) Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 20:1453–1460PubMedPubMedCentralCrossRef
145.
Hollander P, Hill J, Johnson J et al (2019) Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin 35(08):1335–1343PubMedCrossRef
146.
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39PubMedCrossRef
147.
Puckrin R, Saltiel MP, Reynier P et al (2018) SGLT‑2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55(05):503–514PubMedCrossRef
148.
149.
Dave CV, Schneeweiss S, Patorno E (2019) Comparative risk of genital infections associated with sodium glucose co-transporter‑2 inhibitors. Diabetes Obes Metab 21:434–438PubMedCrossRef
150.
Lega IC, Bronskill SE, Campitelli MA et al (2019) Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab 21:2394–2404PubMedCrossRef
151.
McGovern AP, Hogg M, Shields BM et al (2020) Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diab Res Care 8:e1238PubMedPubMedCentralCrossRef
152.
Yang JY, Wang T, Pate V et al (2020) Real-world evidence on sodium-glucose cotransporter‑2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diab Res Care 8:e985PubMedPubMedCentralCrossRef
153.
Silverii GA, Dicembrini I, Monami M et al (2020) Fournier’s gangrene and sodium-glucose co-transporter‑2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:272–275PubMedCrossRef
154.
155.
Scheen AJ (2018) Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol 14(06):326–328PubMedCrossRef
156.
157.
Inzucchi SE, Iliev H, Pfarr E et al (2018) Empagliflozin and assessment of lower limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41:e4–e5PubMedCrossRef
158.
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306PubMedCrossRef
159.
Huang CY, Lee JK (2020) Sodium-glucose co-transporter‑2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals. Diabetes Obes Metab 22:2348–2355PubMedCrossRef
160.
Zhou Z, Jardine M, Perkovic V et al (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program. Diabetologia 62(10):1854–1867PubMedPubMedCentralCrossRef
161.
Perkovic V, Jardine MJ, Neal N et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306PubMedCrossRef
162.
Mahaffey KW, Jardine MJ, Bompoint S et al (2019) Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140:739–750PubMedPubMedCentralCrossRef
163.
Kohler S, Kaspers S, Salsali A et al (2018) Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care 41(08):1809–1816PubMedCrossRef
164.
165.
Tang HL, Li DD, Zhang JJ et al (2016) Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18(12):1199–1206PubMedCrossRef
166.
Li X, Li T, Cheng Y et al (2019) Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev 35:e3170PubMedCrossRef
167.
Hidayat K, Du X, Shi BM (2019) Risk of fracture with dipeptidyl peptidase‑4 inhibitors, glucagon-like peptide‑1 receptor agonists, or sodium-glucose cotransporter‑2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int 30:1923–1940PubMedCrossRef
168.
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300–2303PubMedCrossRef
169.
Monami M, Nreu B, Zannoni S et al (2017) Effects of SGLT2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 130:53–60PubMedCrossRef
170.
Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia 60:1385–1389PubMedCrossRef
171.
Liu J, Li L, Li S et al (2020) Sodium-glucose co-transporter‑2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:1619–1627PubMedCrossRef
172.
Thiruvenkatarajan V, Meyer EJ, Nanjappa N et al (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter‑2 inhibitors: a systematic review. Br J Anaesth 123(01):27–36PubMedCrossRef
173.
Milder DA, Milder TY, Kam PCA (2018) Sodium-glucose co-transporter type‑2 inhibitors: pharmacology and perioperative considerations. Anaesthesia 73:1008–1018PubMedCrossRef
174.
Donnan K, Segar L (2019) SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846:23–29PubMedPubMedCentralCrossRef
175.
Mosenzon O, Wiviott SD, Cahn A et al (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7(08):606–617PubMedCrossRef
176.
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMedCrossRef
177.
Wheeler DC, Stefánsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22–31PubMedCrossRef
178.
Neuen BL, Young T, Heerspink HJL (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845–854PubMedCrossRef
179.
Karagiannis T, Tsapas A, Athanasiadou E et al (2021) GLP‑1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 174:108737PubMedCrossRef
180.
Bae JH, Park EG, Kim S et al (2021) Comparative renal effects of dipeptidyl peptidase‑4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. Endocrinol Metab (Seoul) 36(2):388–400CrossRef
181.
182.
183.
McGuire DK, Zinman B, Inzucchi SE et al (2020) Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol 8:949–959PubMedCrossRef
184.
Wanner C, Inzucchi SE, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMedCrossRef
185.
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621PubMedCrossRef
186.
Verma S, Mazer CD, Fitchett D et al (2018) Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: sub-analysis of the EMPA-REG OUTCOME® randomized trial. Diabetologia 61:1712–1723PubMedPubMedCentralCrossRef
187.
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424PubMedCrossRef
188.
Zou CY, Liu XK, Sang YQ et al (2019) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. A meta-analysis. Medicine 98(49):e18245PubMedPubMedCentralCrossRef
189.
Salah HM, Al’Aref SJ, Khan MS et al (2021) Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update. Am Heart J 233:86–91PubMedCrossRef
190.
191.
192.
Sattar N, McLaren J, Kristensen SL et al (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339PubMedPubMedCentralCrossRef
193.
Ferrannini E, Mark M, Mayoux E et al (2016) CV protection in the EMPA-REG OUTCOME trial: a „thrifty substrate“ hypothesis. Diabetes Care 39:1108–1114PubMedCrossRef
194.
Dutka M, Bobiński R, Ulman-Włodarz I et al (2021) Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Fail Rev 26:603–622PubMedCrossRef
195.
Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:2098–2210PubMedCrossRef
196.
Yurista SR, Chong CR, Badimon JJ et al (2021) Therapeutic potenzial of ketone bodies for patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 77(13):1660–1669PubMedCrossRef
197.
198.
Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425–1435PubMedCrossRef
199.
Rosenstock J, Frias J, Páll D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20(3):520–529PubMedCrossRef
200.
Hollander P, Liu J, Hill J et al (2018) Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther 9(1):193–207PubMedCrossRef
201.
Cherney DZI, Heerspink HJL, Frederich R et al (2020) Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 63:1128–1140PubMedPubMedCentralCrossRef
202.
Cherney DZI, Charbonnel B (2021) Cosentino F effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial; VERTIS CV investigators. Diabetologia 64(6):1256–1267PubMedPubMedCentralCrossRef
203.
204.
205.
Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117–128PubMedCrossRef
206.
Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129–139PubMedCrossRef
207.
Levin PA, Nguyen H, Wittbrodt ET et al (2017) Glucagon-like peptide‑1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 10:123–139PubMedPubMedCentralCrossRef
208.
209.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet 394:131–138PubMedCrossRef
210.
Dagenais GR, Rydén L, Leiter LA et al (2020) Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 19:199PubMedPubMedCentralCrossRef
211.
Lundgren JR, Janus C, Jensen SBK et al (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384:1719–1730PubMedCrossRef
212.
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322PubMedPubMedCentralCrossRef
213.
Verma S, Bhatt DL, Bain SC et al (2018) Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease. Circulation 137(20):2179–2183PubMedCrossRef
214.
Marso SP, Nauck MA, Monk Fries T et al (2018) Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER trial). Am J Cardiol 121:1467–1470PubMedCrossRef
215.
Duan CM, Wan TF, Wang Y et al (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. A systematic review and meta-analysis. Medicine 98(46):e17860PubMedPubMedCentralCrossRef
216.
Mann JFE, Ørsted DD, Buse JB (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848PubMedCrossRef
217.
Kristensen SL, Rørth R, Jhund PS (2019) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7(10):776–785PubMedCrossRef
218.
Liu J, Li L, Deng K et al (2017) Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357:j2499PubMedPubMedCentralCrossRef
219.
Mishriky BM, Cummings DM, Powell JR et al (2019) Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 45:102–109PubMedCrossRef
220.
221.
Wadden TA, Bailey TS, Billings LK, STEP 3 Investigators et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14):1403–1413PubMedCrossRef
222.
Rubino D, Abrahamsson N, Davies M, STEP 4 Investigators et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414–1425PubMedCrossRef
223.
Leiter LA, Bain SC, Hramiak I et al (2019) Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 18:73PubMedPubMedCentralCrossRef
224.
Avgerinos I, Michailidis T, Liakos A et al (2020) Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22:335–345PubMedCrossRef
225.
226.
Nauck MA, Quast DR (2021) Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne) 12:645566CrossRef
227.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319(15):1580–1591PubMedPubMedCentralCrossRef
228.
Dicembrini I, Nreu B, Scatena A et al (2017) Microvascular effects of glucagon-like peptide‑1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54:933–941PubMedCrossRef
229.
Mann JFE, Hansen T, Idorn T et al (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 11:880–893CrossRef
230.
Home PD, Ahrén B, Reusch JEB et al (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: longterm efficacy with or without rescue therapy. Diabetes Res Clin Pract 131:49–60PubMedCrossRef
231.
Ahrén B, Carr MC, Murphy K et al (2017) Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract 126:230–239PubMedCrossRef
232.
Rosenstock J, Nino A, Soffer J et al (2020) Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care 43:2509–2518PubMedPubMedCentralCrossRef
233.
Fudim M, White J, Pagidipati NJ et al (2019) Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes. Insights from the EXSCEL trial. Circulation 140:1613–1622PubMedPubMedCentralCrossRef
234.
Bonora BM, Avogaro A, Fadini GP (2019) Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 56:1051–1060PubMedCrossRef
235.
Jabbour SA, Frías JP, Ahmed A et al (2020) Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION‑8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43(10):2528–2536PubMedPubMedCentralCrossRef
236.
Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon-like peptide‑1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113PubMedCrossRef
237.
van der Aart—van der Beek AB, van Raalte DH, Guja C et al (2020) Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials. Diabetes Obes Metab 22:1556–1566PubMedPubMedCentralCrossRef
238.
Home P, Blonde L, Kalra S et al (2020) Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: a systematic review and Bayesian network meta-analysis. Diabetes Obes Metab 22(11):2179–2188PubMedCrossRef
239.
Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896–907PubMedCrossRef
240.
Frias JP, Nauck MA, Van J et al (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide‑1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 22:938–946PubMedPubMedCentralCrossRef
241.
Nauck MA, Wefers J, Meier JJ (2021) Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol 9(8):525–544PubMedCrossRef
242.
243.
244.
Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of novel dual GIP and GLP‑1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43:1352–1355PubMedPubMedCentralCrossRef
245.
Wilson JM, Nikooienejad A, Robins DA et al (2020) The dual glucose-dependent insulinotropic peptide andglucagon-like peptide‑1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab 22:2451–2459PubMedPubMedCentralCrossRef
246.
Min T, Bain SC (2021) The role of tirzepatide, dual GIP and GLP‑1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther 12:143–157PubMedCrossRef
247.
Vilsbøll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20:889–897PubMedPubMedCentralCrossRef
248.
Monami M, Nreu B, Scatena A et al (2017) Safety issues with glucagon-like peptide‑1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab 19(09):1233–1241PubMedCrossRef
249.
Abd El Aziz M, Cahyadi O, Meier JJ et al (2020) Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 22:699–704PubMedCrossRef
250.
Cao C, Yang S, Zhou Z (2019) GLP‑1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66:157–165PubMedCrossRef
251.
Azoulay L, Filion KB, Platt RW et al (2016) Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 176(10):1464–1473PubMedCrossRef
252.
Wang T, Wang F, Gou Z et al (2015) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1324 515 patients from observational studies. Diabetes Obes Metab 17:32–41PubMedCrossRef
253.
254.
Piccoli GF, Mesquita LA, Stein C et al (2021) Do GLP‑1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab 106(3):912–921PubMedCrossRef
255.
Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124PubMedCrossRef
256.
Mantsiou C, Karagiannis T, Kakotrichi P et al (2020) Glucagon-like peptide‑1 receptor agonists and sodium-glucose co-transporter‑2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22(10):1857–1868PubMedCrossRef
257.
Russell-Jones D, Pouwer F, Khunti K (2018) Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 20:488–496PubMedCrossRef
258.
Landgraf R, Aberle J (2021) Hundert Jahre – Insulin bleibt aktuell und notwendig. Diabetologie 16:1–13
259.
Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377(08):723–732PubMedPubMedCentralCrossRef
260.
Pieber TR, Marso SP, McGuire DK et al (2018) DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 61:58–65PubMedCrossRef
261.
Lau IT, Lee KF, So WY et al (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 10:273–284PubMedPubMedCentralCrossRef
262.
Ritzel R, Roussel R, Giaccari A et al (2018) Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‑year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 20:541–548PubMedCrossRef
263.
Bonadonna RC, Renard E, Cheng A et al (2018) Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract 142:19–25PubMedCrossRef
264.
Linnebjerg H, Lam EC, Seger ME et al (2015) Comparison of the pharmacokinetics and pharmacodynamics of LY2963 016 insulin glargine and EU and US-approved versions of lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care 38:2226–2233PubMedCrossRef
265.
Rosenstock J, Hollander P, Bhargava A et al (2015) Similar efficacy and safety of LY2963 016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (ELEMENT 2 study). Diabetes Obes Metab 17:734–741PubMedCrossRef
266.
Yamada T, Kamata R, Ishinohachi K et al (2018) Biosimilar vs originator insulins: systematic review and meta-analysis. Diabetes Obes Metab 20:1787–1792PubMedCrossRef
267.
But A, De Bruin ML, Bazelier MT et al (2017) Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 60:1691–1703PubMedPubMedCentralCrossRef
268.
Maiorino MI, Chiodini P, Bellastella G et al (2017) Insulin and glucagon-like peptide1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 40:614–624PubMedCrossRef
269.
Guja C, Frías JP, Somogyi A et al (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION‑7 randomized study. Diabetes Obes Metab 20:1602–1161PubMedPubMedCentralCrossRef
270.
Rodbard HW, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103(06):2291–2301PubMedPubMedCentralCrossRef
271.
272.
Gentile S, Fusco A, Colarusso S et al (2018) A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U‑100 versus concentrated lispro insulin U‑200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 17(05):445–450PubMedCrossRef
273.
Heise T, Hövelmann U, Brøndsted L et al (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17:682–688PubMedPubMedCentralCrossRef
274.
Bowering K, Case C, Harvey J et al (2017) Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the ONSET 2 trial. Diabetes Care 40(07):951–957PubMedCrossRef
275.
Leohr J, Dellva MA, Coutant DE et al (2020) Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog(®) (lispro) in patients with type 2 diabetes mellitus: a phase I randomized, crossover study. Clin Pharmacokinet 59(12):1601–1610PubMedPubMedCentralCrossRef
276.
277.
Lawall H, Huppert P, Rümenapf G et al (2015) Periphere arterielle Verschlusskrankheit (PAVK), Diagnostik, Therapie und Nachsorge (AWMF-Register Nr. 065-003)
278.
279.
280.
281.
Roeb E, Steffen HM, Bantel H et al (2015) S2k-Leitlinie: Nicht-alkoholische Fettlebererkrankungen (AWMF-Register Nr. 021-025)
282.
Wang R, Song Y, Yan Y et al (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis 254:193–199PubMedCrossRef
283.
284.
285.
Metadaten
Titel
Therapie des Typ-2-Diabetes
verfasst von
Prof. Dr. med. Rüdiger Landgraf
Jens Aberle
Andreas L. Birkenfeld
Baptist Gallwitz
Monika Kellerer
Harald H. Klein
Dirk Müller-Wieland
Michael A. Nauck
Tobias Wiesner
Erhard Siegel
Publikationsdatum
13.06.2022
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 5/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-022-00921-5

Weitere Artikel der Ausgabe 5/2022

Die Diabetologie 5/2022 Zur Ausgabe

Journal Club

Therapieziele und Lebenserwartung bei Diabetes mellitus Typ 2

DDG Praxisempfehlungen

DDG Praxisempfehlungen: Diabetes mellitus im Alter

Leitthema

Adipositas und Ernährung

Leitthema

Diabetes und Schwangerschaft – Update 2022

CME

Diabetische Ketoazidose – erkennen, behandeln, vermeiden

DDG Praxisempfehlungen

DDG Praxisempfehlungen: Diabetes mellitus und Herz

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise